StockData
Vistagen Therapeutics, Inc. logo

Vistagen Therapeutics, Inc. (VTGN) stock

VTGNNasdaqPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 9/3078% below fair value
$0.19+0.00 (+2.01%)

Close on Nov 17, 2026Market cap $8.34MP/E –Yield –

Vistagen Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

No pe ratio figures for Vistagen Therapeutics

Vistagen Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

More Vistagen Therapeutics figures

See a number that looks wrong?